Fairvalue-Calculator Fairvalue-Calculator

Galenica AG (GALE) Fair Value & Analysis

Healthcare · CH · Market cap CHF 4.2B

PriceCHF 84.60
Fair ValueCHF 75.00
Upside-11.3%
Quality95/100
Evidence: High Range CHF 48.05 – CHF 99.96

Analysis

Galenica AG (GALE) currently trades at CHF 84.60, while our model-based Fair Value estimate is CHF 75.00 — implying the stock looks roughly 11.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels. The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as…

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) -81% Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -38% Sigma Healthcare Limited (SIGGF) -73% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +183%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.